恩格列净联合利拉鲁肽治疗2型糖尿病伴心力衰竭的效果分析  

Effect analysis of engliazine combined with liraglutide in the treatment of type 2 diabetes mellitus with heart failure

作　　者：郭明笛[1] 李雪粉[2] GUO Ming-di;LI Xue-fen(Department of Cardiac Surgery of Teda International Cardiovascular Hospital,Tianjin 300450,China;不详)

机构地区：[1]泰达国际心血管病医院心外科,天津300450 [2]泰达国际心血管病医院内分泌科,天津300450

出　　处：《中国处方药》2023年第8期127-131,共5页Journal of China Prescription Drug

摘　　要：目的 探究恩格列净联合利拉鲁肽治疗2型糖尿病伴心衰患者的效果。方法 选取2020年3月~2022年12月在泰达国际心血管病医院就诊的2型糖尿病伴心衰患者122例,按照随机数字法分为对照组(n=61)和观察组(n=61),其中对照组采用利拉鲁肽治疗,观察组采用恩格列净联合利拉鲁肽治疗。评估两组患者的临床疗效、血糖水平、心功能、血清指标、不良反应及生活质量。结果 观察组的总有效率、简易生活质量评价量表(SF-36)中各个项目评分、左心室射血分数(LVEF)、心输出量(CO)、每搏输出量(SV)水平均高于对照组(P <0.05);治疗后观察组的餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、空腹血糖(FPG)、B型利钠肽(BNP)、N末端B型利钠肽(NT-proBNP)、超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)水平均低于对照组(P <0.05)。结论 2型糖尿病伴心衰患者采用恩格列净联合利拉鲁肽治疗效果显著,降低血糖水平,改善心功能,调节血清指标,提升患者的生活质量。Objective To explore the effect of engliazine combined with liraglutide in the treatment of patients with type 2 diabetes mellitus with heart failure.Methods A total of 122 patients with type 2 diabetes mellitus and heart failure admitted to Teda International Cardiovascular Hospital from March 2020 to December 2022 were selected and divided into control group(n = 61) and observation group(n = 61) according to random number method.The control group was treated with liraglutide,and the observation group was treated with engliazine combined with liraglutide.The clinical efficacy,blood glucose level,cardiac function,serum indexes,adverse reactions and quality of life of the two groups were evaluated.Results After treatment,the total effective rate,scores of SF-36,LVEF,SV and CO levels in observation group were higher than those in control group(P<0.05).After treatment,the levels of 2 hPG,Hb A1c,FPG,BNP,NT-pro BNP,hs-CRP and IL-6 in observation group were lower than those in control group(P<0.05).Conclusion In patients with type 2 diabetes mellitus and heart failure,engliazine combined with liraglutide can significantly reduce blood glucose levels,improve cardiac function,regulate serum indexes,and improve patients' quality of life.

关 键 词：恩格列净 利拉鲁肽 2型糖尿病 心衰 血糖水平 

分 类 号：R587.2[医药卫生—内分泌] R541.6[医药卫生—内科学]